Volume 4 (2016)

Review Articles

Feasibility and attractiveness of indication value-based pricing in key EU countries Mathias Flume, Marc Bardou, Stefano Capri, Oriol Sola-Morales, David Cunningham, Lars-Ake Levin, Nicolas Touchot

Original Research Articles

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials Eve Hanna, Cecile Rémuzat, Pascal Auquier, Mondher Toumi
Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles Edward Gibson, Najida Begum, Federico Martinón-Torres, Marco Aurélio Safadi, Alfred Sackeyfio, Judith Hackett, Sankarasubramanian Rajaram
Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole Craig Bennison, Stephanie Stephens, Benedicte Lescrauwaet, Ben van Hout, Timothy L. Jackson
Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations Katia Thokagevistk, Aurélie Millier, Leslie Lenert, Shamil Sadikhov, Santiago Moreno, Mondher Toumi
Advanced therapy medicinal products: current and future perspectives Eve Hanna, Cécile Rémuzat, Pascal Auquier, Mondher Toumi
The value of innovation under value-based pricing Santiago G, Moreno, Joshua A. Ray
Drug Pricing Reform in China: analysis of piloted approaches and potential impact of the reform Yixi Chen, Shanlian Hu, Peng Dong, Åsa Kornfeld, Patrycja Jaros, Jing Yan, Fangfang Ma, Mondher Toumi

Best Practice Papers